[S02DA03, antipyrine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Spironolactone.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.]
[J01GA01, streptomycin, Spironolactone may increase the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Spironolactone.]
[A02BX02, sucralfate, Spironolactone may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Spironolactone may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Spironolactone.]
[J01EC01, sulfamethoxazole, Spironolactone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, Spironolactone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[M01AB02, sulindac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Spironolactone.]
[M01AX04, apazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Spironolactone.]
[L02BA01, tamoxifen, Tamoxifen may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N05CD07, temazepam, Spironolactone may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Spironolactone.]
[B01AE07, dabigatran etexilate, Spironolactone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Spironolactone may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Spironolactone may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Spironolactone.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Spironolactone.]
[P02CA02, thiabendazole, Spironolactone may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Spironolactone may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Spironolactone.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Thioridazine.]
[G04BE06, moxisylyte, Spironolactone may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Spironolactone may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Spironolactone may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Spironolactone may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Spironolactone may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Spironolactone may increase the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB05, tolazamide, Spironolactone may increase the excretion rate of Tolazamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Spironolactone is combined with Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Spironolactone.]
[M02AA21, tolmetin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Spironolactone.]
[N02AX02, tramadol, Spironolactone may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Spironolactone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Spironolactone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Spironolactone.]
[N05CD05, triazolam, Spironolactone may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, Spironolactone may increase the hypotensive activities of Trichlormethiazide.]
[A16AX12, trientine, Spironolactone may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Spironolactone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AA05, trimebutine, Spironolactone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Spironolactone.]
[C02BA01, trimethaphan, Spironolactone may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Spironolactone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Spironolactone.]
[M03AA02, tubocurarine, Spironolactone may increase the neuromuscular blocking activities of Tubocurarine.]
[R03DX07, roflumilast, Spironolactone may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Spironolactone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA14, oxyquinoline, Spironolactone may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BX03, abiraterone, The therapeutic efficacy of Abiraterone can be decreased when used in combination with Spironolactone.]
[S01AA28, vancomycin, Spironolactone may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX21, ezogabine, Spironolactone may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Spironolactone may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Spironolactone.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Spironolactone.]
[N06AX09, viloxazine, Spironolactone may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CA01, vinblastine, Vinblastine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[C04AX07, vincamine, Spironolactone may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, Spironolactone may decrease the excretion rate of Vincristine which could result in a higher serum level.]
[B03BA01, vitamin B12, Spironolactone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Spironolactone may increase the excretion rate of Warfarin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[C03BA10, xipamide, Spironolactone may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Spironolactone.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[M05BA05, tiludronic acid, Spironolactone may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Spironolactone may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC04, rabeprazole, Spironolactone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Drospirenone.]
[V03AC02, deferiprone, Spironolactone may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Spironolactone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Spironolactone may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Spironolactone may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, Atenolol may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[M03AC04, atracurium, Spironolactone may increase the neuromuscular blocking activities of Atracurium.]
[S01FA01, atropine, Spironolactone may decrease the excretion rate of Atropine which could result in a higher serum level.]
[M01CB03, auranofin, Spironolactone may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[B03XA04, peginesatide, Spironolactone may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Spironolactone may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Spironolactone may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Spironolactone may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Spironolactone may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Spironolactone.]
[M03BX01, baclofen, Spironolactone may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA11, lorcaserin, Spironolactone may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, The therapeutic efficacy of Mirabegron can be decreased when used in combination with Spironolactone.]
[L02BB04, enzalutamide, The metabolism of Enzalutamide can be decreased when combined with Spironolactone.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Linaclotide.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Spironolactone.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Spironolactone.]
[C01AA01, acetyldigitoxin, Spironolactone may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level.]
[D02BA02, octinoxate, Spironolactone may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Spironolactone.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Lercanidipine.]
[V09IX04, fluorodeoxyglucose F18, Spironolactone may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Spironolactone.]
[V08CA11, gadofosveset, Spironolactone may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Spironolactone.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Spironolactone.]
[A16AX08, teduglutide, Spironolactone may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bencyclane.]
[A10BH04, alogliptin, Spironolactone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX09, glycerol phenylbutyrate, Spironolactone may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, Spironolactone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benorilate is combined with Spironolactone.]
[A10BK02, canagliflozin, Spironolactone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[M04AB03, benzbromarone, Spironolactone may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Spironolactone is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Spironolactone.]
[L03AA12, ancestim, Spironolactone may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N04AC01, benztropine, Spironolactone may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Spironolactone.]
[R02AX03, benzydamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Spironolactone.]
[L01EE01, trametinib, Spironolactone may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Spironolactone.]
[V09AX05, florbetapir F-18, Spironolactone may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Spironolactone.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Spironolactone is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Spironolactone.]
[A10BJ03, lixisenatide, Spironolactone may increase the excretion rate of Lixisenatide which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[C02KX04, macitentan, Spironolactone may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Spironolactone.]
[G03AC08, etonogestrel, Spironolactone may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[J05AP08, sofosbuvir, Spironolactone may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Spironolactone.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.]
[N05CH03, tasimelteon, Spironolactone may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA32, apremilast, Spironolactone may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Spironolactone may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Spironolactone.]
[V03AB34, fomepizole, Spironolactone may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Spironolactone.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Spironolactone.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Spironolactone.]
[V08AA01, diatrizoic acid, Spironolactone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Spironolactone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Spironolactone is combined with Phenolphthalein.]
[A06AH03, naloxegol, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Naloxegol.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Spironolactone is combined with Bisacodyl.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Spironolactone.]
[B01AF03, edoxaban, Spironolactone may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N02BE01, acetaminophen, Spironolactone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Spironolactone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA06, eluxadoline, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Eluxadoline.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Spironolactone.]
[M01AB11, acemetacin, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Spironolactone.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Spironolactone.]
[V03AB37, idarucizumab, Spironolactone may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG03, ixazomib, Spironolactone may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Spironolactone.]
[M04AB05, lesinurad, Spironolactone may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE16, alminoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Spironolactone.]
[N03AX23, brivaracetam, Spironolactone may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA08, bromazepam, Spironolactone may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Spironolactone.]
[A02AD05, aluminum magnesium silicate, Spironolactone may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone.]
[C03CA02, bumetanide, Spironolactone may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Spironolactone.]
[C07AA19, bupranolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Spironolactone.]
[N05BE01, buspirone, Spironolactone may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, Spironolactone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA03, clofezone, Spironolactone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Butorphanol.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Spironolactone.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Plecanatide.]
[A07EC04, balsalazide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Spironolactone.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Spironolactone.]
[A06AH05, naldemedine, Spironolactone may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Spironolactone may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Spironolactone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Benazepril.]
[P01CA02, benznidazole, Spironolactone may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Spironolactone.]
[J05AF06, abacavir, Spironolactone may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N07XX13, valbenazine, Spironolactone may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Spironolactone.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Spironolactone.]
[J01MA23, delafloxacin, Spironolactone may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC06, capecitabine, Spironolactone may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Spironolactone.]
[C07AB07, bisoprolol, Spironolactone may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Spironolactone.]
[J05AG03, efavirenz, Spironolactone may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Nesiritide.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Canrenone.]
[R03BA02, budesonide, Spironolactone may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bumadizone is combined with Spironolactone.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Spironolactone.]
[R06AX18, acrivastine, Spironolactone may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Captopril.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Spironolactone.]
[N03AF01, carbamazepine, Spironolactone may increase the excretion rate of Carbamazepine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Spironolactone is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Spironolactone.]
[L04AA37, baricitinib, Spironolactone may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD14, ceftibuten, Spironolactone may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Spironolactone may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Spironolactone.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Spironolactone.]
[A16AX14, migalastat, Spironolactone may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, Spironolactone may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01GX12, cetirizine, Spironolactone may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[D08AE05, chloroxylenol, Spironolactone may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Spironolactone.]
[L01AD01, carmustine, Spironolactone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Spironolactone.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Spironolactone is combined with Prucalopride.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cilazapril.]
[B01AC23, cilostazol, Spironolactone may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA09, clarithromycin, Spironolactone may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[N06BA14, solriamfetol, Spironolactone may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA09, clobazam, Spironolactone may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Spironolactone is combined with Castor oil.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Candesartan is combined with Spironolactone.]
[J01DC04, cefaclor, Spironolactone may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[J01DB05, cefadroxil, Spironolactone may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC05, cefotetan, Spironolactone may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD02, ceftazidime, Spironolactone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, Spironolactone may increase the hypotensive activities of Cicletanine.]
[J01DD04, ceftriaxone, Spironolactone may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX11, pitolisant, Spironolactone may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Spironolactone.]
[C03AA09, cyclothiazide, Spironolactone may increase the hypotensive activities of Cyclothiazide.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Spironolactone.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Spironolactone is combined with Dantron.]
[J01XX09, daptomycin, Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, Spironolactone may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB09, cephradine, Spironolactone may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[M09AX08, golodirsen, Spironolactone may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA12, dexpanthenol, Spironolactone may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dezocine.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Spironolactone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Spironolactone.]
[R02AA03, dichlorobenzyl alcohol, Spironolactone may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Spironolactone may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Spironolactone.]
[C08CA16, clevidipine, Spironolactone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA06, methoserpidine, Spironolactone may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Spironolactone.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Spironolactone.]
[M01AC04, droxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Spironolactone.]
[V08CA05, mangafodipir, Spironolactone may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA27, dexketoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Spironolactone.]
[C08CA17, levamlodipine, Spironolactone may increase the hypotensive activities of Levamlodipine.]
[L01FX15, belantamab mafodotin, Spironolactone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[N02AX07, oliceridine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Spironolactone.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[A10BB02, chlorpropamide, Spironolactone may increase the excretion rate of Chlorpropamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Spironolactone.]
[M03BB03, chlorzoxazone, Spironolactone may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ethenzamide is combined with Spironolactone.]
[C10AC01, cholestyramine resin, The risk or severity of hyperkalemia and metabolic acidosis can be increased when Cholestyramine is combined with Spironolactone.]
[N02BA03, choline salicylate, Spironolactone may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Spironolactone.]
[M02AA06, etofenamate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Spironolactone.]
[M01AX25, chondroitin sulfates, Spironolactone may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Spironolactone is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Spironolactone.]
[C01CA19, fenoldopam, Spironolactone may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Spironolactone may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA08, fluocinolone acetonide, Spironolactone may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01JA01, fluorescein, Spironolactone may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[N02BG07, flupirtine, Spironolactone may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Spironolactone.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Spironolactone.]
[H04AA02, dasiglucagon, Spironolactone may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[V08CA04, gadoteridol, Spironolactone may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cinnarizine.]
[S03AA07, ciprofloxacin, Spironolactone may increase the arrhythmogenic activities of Ciprofloxacin.]
[L01XA01, cisplatin, Spironolactone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Spironolactone.]
[V09AB03, ioflupane I-123, Spironolactone may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Spironolactone may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Spironolactone may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Spironolactone.]
[A10BB12, glimepiride, Glimepiride may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Spironolactone.]
[N01BB10, levobupivacaine, Spironolactone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA04, clomipramine, Spironolactone may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Spironolactone may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The therapeutic efficacy of Clonidine can be decreased when used in combination with Spironolactone.]
[J05AH02, oseltamivir, Spironolactone may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A05BA08, glycyrrhizic acid, Spironolactone may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH02, clozapine, Spironolactone may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KB01, metyrosine, Spironolactone may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proquazone is combined with Spironolactone.]
[R05DA04, codeine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Spironolactone may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Spironolactone is combined with Desflurane.]
[A04AA03, tropisetron, Spironolactone may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Spironolactone may increase the excretion rate of Nateglinide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Imidazole salicylate is combined with Spironolactone.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Spironolactone.]
[B01AC10, indobufen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indobufen is combined with Spironolactone.]
[J05AB14, valganciclovir, Spironolactone may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Spironolactone may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Spironolactone may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Spironolactone may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Spironolactone may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Spironolactone may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Spironolactone.]
[C01AA06, lanatoside C, Spironolactone may decrease the excretion rate of Lanatoside C which could result in a higher serum level.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Spironolactone.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Spironolactone.]
[M01AH04, parecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Spironolactone.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bemiparin.]
[S01AD03, acyclovir, Spironolactone may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Spironolactone may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Spironolactone.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Spironolactone.]
[C08CA09, lacidipine, Spironolactone may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Lactitol.]
[N03AX09, lamotrigine, Spironolactone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be decreased when used in combination with Spironolactone.]
[M01AB09, lonazolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lonazolac is combined with Spironolactone.]
[R06AX13, loratadine, Spironolactone may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Loxoprofen is combined with Spironolactone.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium carbonate.]
[C08CA11, manidipine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Manidipine.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Mepindolol.]
[J01DH02, meropenem, Spironolactone may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Methoxyphenamine can be decreased when used in combination with Spironolactone.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Eplerenone.]
[N05AD03, metylperon, Spironolactone may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, Spironolactone may increase the hypotensive activities of Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Spironolactone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Spironolactone.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Spironolactone.]
[S01XA18, cyclosporine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Spironolactone.]
[C09AA13, moexipril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Moexipril.]
[C10AA07, rosuvastatin, Spironolactone may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[M02AA02, mofebutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mofebutazone is combined with Spironolactone.]
[M01AX22, morniflumate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Morniflumate is combined with Spironolactone.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Spironolactone is combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Spironolactone.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Spironolactone.]
[M01AH05, etoricoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Spironolactone.]
[L01AX04, dacarbazine, Spironolactone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Spironolactone.]
[L01DB02, daunorubicin, Spironolactone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C02CC04, debrisoquin, Spironolactone may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Spironolactone.]
[N07BB05, nalmefene, Spironolactone may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of hyperkalemia can be increased when Potassium lactate is combined with Spironolactone.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Spironolactone.]
[S01GX04, nedocromil, Spironolactone may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, Spironolactone may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Spironolactone.]
[L02BB02, nilutamide, Spironolactone may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Spironolactone.]
[M03AC11, cisatracurium, Spironolactone may increase the neuromuscular blocking activities of Cisatracurium.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Spironolactone.]
[R05DA06, normethadone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Spironolactone may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC03, olsalazine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olsalazine is combined with Spironolactone.]
[N06AA01, desipramine, Spironolactone may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA07, deslanoside, Spironolactone may decrease the excretion rate of Deslanoside which could result in a higher serum level.]
[H01BA02, desmopressin, Spironolactone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CH02, indigo carmine, Spironolactone may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH03, ertapenem, Spironolactone may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Spironolactone is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Spironolactone.]
[S03BA01, dexamethasone, Dexamethasone may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA02, dextroamphetamine, Spironolactone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Spironolactone.]
[N02AC01, dextromoramide, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dextromoramide.]
[N07BC06, heroin, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Spironolactone may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Spironolactone may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Spironolactone may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Diazoxide.]
[R05DA08, pholcodine, Spironolactone may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Spironolactone.]
[A03AA07, dicyclomine, Spironolactone may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Spironolactone may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Spironolactone may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Spironolactone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Pipamperone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Spironolactone.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Spironolactone.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Spironolactone.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[D07XC04, diflucortolone, Spironolactone may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA11, diflunisal, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Spironolactone.]
[C01AA04, digitoxin, Spironolactone may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Spironolactone.]
[C02DB01, dihydralazine, Spironolactone may increase the hypotensive activities of Dihydralazine.]
[C10AX09, ezetimibe, Spironolactone may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Spironolactone may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02AA03, hydromorphone, Spironolactone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Spironolactone may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, Spironolactone may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Spironolactone.]
[H03BC01, potassium perchlorate, The risk or severity of hyperkalemia can be increased when Potassium perchlorate is combined with Spironolactone.]
[V03AB04, pralidoxime, Spironolactone may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Spironolactone.]
[V03AB09, dimercaprol, Spironolactone may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Spironolactone.]
[M02AX03, dimethyl sulfoxide, Spironolactone may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propyphenazone is combined with Spironolactone.]
[M01AB14, proglumetacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proglumetacin is combined with Spironolactone.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Quinapril.]
[B01AC07, dipyridamole, Spironolactone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Spironolactone.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ramipril.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Spironolactone.]
[S01AX06, resorcinol, Spironolactone may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Spironolactone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AA04, disulfiram, Spironolactone may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[N05AX08, risperidone, Spironolactone may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Spironolactone may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Spironolactone may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tolvaptan.]
[G04BE08, tadalafil, Spironolactone may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Spironolactone.]
[C02KX02, ambrisentan, Spironolactone may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Spironolactone.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Spironolactone.]
[H05BA01, salmon calcitonin, Spironolactone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Spironolactone.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Spironolactone.]
[C01CA04, dopamine, Spironolactone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA12, doxepin, Spironolactone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sennosides.]
[L01DB01, doxorubicin, Spironolactone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[J01AA02, doxycycline, Spironolactone may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sevoflurane.]
[A08AA10, sibutramine, Spironolactone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Spironolactone.]
[V03AG05, sodium phosphate, Spironolactone may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium sulfate.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Spirapril.]
[R03DA01, dyphylline, Spironolactone may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Spironolactone may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Spironolactone may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Talinolol.]
[L01AX03, temozolomide, Spironolactone may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Spironolactone.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Spironolactone.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tertatolol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Spironolactone.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic acid is combined with Spironolactone.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Spironolactone.]
[N06BA09, atomoxetine, Spironolactone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, Spironolactone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Spironolactone.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Trandolapril.]
[N05CC01, chloral hydrate, Spironolactone may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Spironolactone.]
[C02CA06, urapidil, Spironolactone may increase the hypotensive activities of Urapidil.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Spironolactone.]
[N06AX16, venlafaxine, Spironolactone may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Spironolactone.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Spironolactone.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Spironolactone.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Spironolactone.]
[N03AX15, zonisamide, Spironolactone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Spironolactone.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Spironolactone.]
[L01XA02, carboplatin, Spironolactone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Spironolactone.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Spironolactone is combined with Iloprost.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Spironolactone.]
[L03AX05, pidotimod, Spironolactone may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N05CD04, estazolam, Spironolactone may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Spironolactone may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Spironolactone.]
[G03CA57, estrogens, conjugated (USP), Spironolactone may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Spironolactone may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Spironolactone.]
[V08CA03, gadodiamide, Spironolactone may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Amifostine.]
[C01BD05, ibutilide, Spironolactone may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ethosuximide.]
[M01AC06, meloxicam, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Ethylmorphine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Spironolactone.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Spironolactone.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus.]
[R06AX11, astemizole, Spironolactone may decrease the excretion rate of Astemizole which could result in a higher serum level.]
[R06AX12, terfenadine, Terfenadine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[P01AX07, trimetrexate, Spironolactone may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Spironolactone may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[L02AE02, leuprolide, Spironolactone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Spironolactone may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Spironolactone may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Spironolactone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Spironolactone may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, Spironolactone may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Spironolactone.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Spironolactone.]
[N02AB03, fentanyl, Spironolactone may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Spironolactone.]
[L01BB06, clofarabine, Spironolactone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Spironolactone may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Spironolactone may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Spironolactone.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[J02AC01, fluconazole, Spironolactone may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AX01, flucytosine, Spironolactone may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB25, flumazenil, Spironolactone may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Flunarizine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Spironolactone.]
[L01BC09, floxuridine, Spironolactone may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Spironolactone.]
[N05CD01, flurazepam, Spironolactone may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Spironolactone.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fluspirilene.]
[L02BB01, flutamide, Spironolactone may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Spironolactone may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Spironolactone may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Spironolactone.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Spironolactone.]
[M03AA01, alcuronium, Spironolactone may increase the neuromuscular blocking activities of Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Spironolactone.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Spironolactone.]
[M03AC02, gallamine, Spironolactone may increase the neuromuscular blocking activities of Gallamine.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Gallopamil.]
[S01AD09, ganciclovir, Spironolactone may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Spironolactone.]
[C10AB04, gemfibrozil, Spironolactone may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Spironolactone may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Spironolactone.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[A10BB07, glipizide, Spironolactone may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Spironolactone.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Spironolactone.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Spironolactone.]
[M01CB04, aurothioglucose, Spironolactone may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Spironolactone may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fosinopril.]
[S01EX01, guanethidine, Spironolactone may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Spironolactone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Spironolactone.]
[N05AD01, haloperidol, Spironolactone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Spironolactone is combined with Halothane.]
[N05AH04, quetiapine, Spironolactone may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX13, idebenone, Spironolactone may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Spironolactone.]
[M04AA01, allopurinol, Spironolactone may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Losartan is combined with Spironolactone.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Heparin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Spironolactone may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Spironolactone.]
[C01CE02, milrinone, Spironolactone may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Spironolactone.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Spironolactone.]
[C08CA10, nilvadipine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Spironolactone.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Perindopril.]
[C02DB02, hydralazine, Spironolactone may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, The risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Spironolactone.]
[S01XA07, aluminum potassium sulfate, The risk or severity of hyperkalemia can be increased when Potassium alum is combined with Spironolactone.]
[A12BA02, potassium citrate, The risk or severity of hyperkalemia can be increased when Potassium citrate is combined with Spironolactone.]
[V03AB33, hydroxocobalamin, Spironolactone may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Spironolactone may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Spironolactone.]
[B05AA07, hetastarch, Spironolactone may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Spironolactone.]
[R02AX02, ibuprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Spironolactone.]
[B05XA08, sodium acetate, Spironolactone may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium tartrate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Spironolactone.]
[N01AH03, sufentanil, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Spironolactone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Spironolactone.]
[R01AD07, tixocortol, Spironolactone may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Spironolactone.]
[L01CE01, topotecan, Spironolactone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Spironolactone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Spironolactone.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Indoramin.]
[A11HA07, inositol, Spironolactone may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, Spironolactone may increase the excretion rate of Milnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA28, varenicline, Spironolactone may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Spironolactone.]
[N05BA12, alprazolam, Spironolactone may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Spironolactone may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Spironolactone.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Alprenolol.]
[V03AB01, ipecac, Spironolactone may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Spironolactone.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Spironolactone.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Spironolactone.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Spironolactone is combined with Isoflurane.]
[J04AC01, isoniazid, Spironolactone may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AX05, inosine pranobex, Spironolactone may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Spironolactone.]
[C01DA14, isosorbide mononitrate, Spironolactone may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Spironolactone may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Spironolactone.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Spironolactone.]
[C02KD01, ketanserin, Spironolactone may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Spironolactone may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Spironolactone.]
[M02AA10, ketoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Spironolactone.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Spironolactone.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Rotigotine.]
[D10AX03, azelaic acid, Spironolactone may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Spironolactone.]
[C07AG01, labetalol, Spironolactone may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Spironolactone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Spironolactone may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Spironolactone is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Lubiprostone.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Spironolactone is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lidoflazine.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Amiloride.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Spironolactone.]
[N05BA06, lorazepam, Spironolactone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Spironolactone.]
[B05XA11, magnesium chloride, Spironolactone may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Spironolactone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.]
[N06AA21, maprotiline, Spironolactone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Spironolactone may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Spironolactone.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Spironolactone.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Spironolactone is combined with Frangula purshiana bark.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dalteparin.]
[N06DX01, memantine, Spironolactone may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Spironolactone may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA11, mephentermine, The therapeutic efficacy of Mephentermine can be decreased when used in combination with Spironolactone.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Spironolactone.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Spironolactone.]
[N01BB03, mepivacaine, Spironolactone may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Spironolactone may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Spironolactone may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Spironolactone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Spironolactone.]
[A10BA02, metformin, Spironolactone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BC02, methadone, Spironolactone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Spironolactone.]
[J05AF05, lamivudine, Spironolactone may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Spironolactone is combined with Methazolamide.]
[H03BB02, methimazole, Spironolactone may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BA04, pemetrexed, Spironolactone may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Spironolactone.]
[A11HA02, pyridoxine, Spironolactone may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Spironolactone is combined with Ziconotide.]
[L04AX03, methotrexate, Spironolactone may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Spironolactone.]
[D05BA02, methoxsalen, Spironolactone may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Spironolactone is combined with Methylcellulose.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Spironolactone.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Spironolactone.]
[G03EK01, methyltestosterone, Spironolactone may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Spironolactone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Spironolactone may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Spironolactone may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CD01, metyrapone, Spironolactone may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB03, aminopyrine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Spironolactone.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Parnaparin.]
[N05CD08, midazolam, Spironolactone may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Spironolactone.]
[G03XB01, mifepristone, Spironolactone may decrease the excretion rate of Mifepristone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tinzaparin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Spironolactone is combined with Mineral oil.]
[J05AH01, zanamivir, Spironolactone may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Spironolactone.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Spironolactone.]
[L01XX23, mitotane, The therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone.]
[L03AC01, aldesleukin, Spironolactone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Spironolactone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Spironolactone.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Spironolactone.]
[A04AA05, palonosetron, Spironolactone may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, Spironolactone may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Spironolactone.]
[G04BA01, ammonium chloride, Spironolactone may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Spironolactone.]
[L04AA06, mycophenolic acid, Spironolactone may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC03, vecuronium, Spironolactone may increase the neuromuscular blocking activities of Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Spironolactone.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Spironolactone.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Spironolactone.]
[C07AA12, nadolol, Spironolactone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Spironolactone may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Spironolactone.]
[N02AF02, nalbuphine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, Spironolactone may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BB04, naltrexone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Naltrexone.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Spironolactone.]
[N06BA01, amphetamine, Spironolactone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Spironolactone.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Spironolactone is combined with Duloxetine.]
[N04BX01, tolcapone, Spironolactone may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AH06, remifentanil, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Spironolactone.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Spironolactone is combined with Levosimendan.]
[B01AC17, tirofiban, Spironolactone may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Spironolactone is combined with Amphotericin B.]
[S01AA19, ampicillin, Spironolactone may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Spironolactone may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX23, desvenlafaxine, Spironolactone may increase the excretion rate of Desvenlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Spironolactone.]
[J05AB11, valacyclovir, Spironolactone may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Spironolactone may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Spironolactone.]
[C08CA04, nicardipine, The metabolism of Nicardipine can be decreased when combined with Spironolactone.]
[C08CA05, nifedipine, Spironolactone may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Niflumic acid is combined with Spironolactone.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Spironolactone is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Nimodipine is combined with Spironolactone.]
[C08CA07, nisoldipine, Spironolactone may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, Spironolactone may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Spironolactone may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Nitrofurantoin may increase the hyperkalemic activities of Spironolactone.]
[N05CF03, zaleplon, Spironolactone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Spironolactone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Spironolactone may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Spironolactone.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Spironolactone.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Reviparin.]
[S02AA16, ofloxacin, Spironolactone may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Spironolactone.]
[N02AA02, opium, Spironolactone may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Spironolactone.]
[G04CA02, tamsulosin, Spironolactone may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AC01, ouabain, Spironolactone may decrease the excretion rate of Ouabain which could result in a higher serum level.]
[J01CF04, oxacillin, Spironolactone may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Spironolactone may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Oxycodone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Spironolactone.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Spironolactone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Spironolactone.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Danaparoid.]
[N02AX06, tapentadol, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, Spironolactone may increase the neuromuscular blocking activities of Pancuronium.]
[J04AB30, capreomycin, Spironolactone may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Spironolactone.]
[G04BD11, fesoterodine, Spironolactone may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Spironolactone may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Spironolactone may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Spironolactone.]
[L01XX08, pentostatin, Spironolactone may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD03, pentoxifylline, Spironolactone may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Spironolactone.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Perhexiline.]
[N02AD02, phenazocine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Spironolactone may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Spironolactone.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Spironolactone.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Spironolactone is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Spironolactone.]
[V03AB36, phentolamine, Spironolactone may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Spironolactone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Spironolactone.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Spironolactone.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Spironolactone.]
[S01AE05, levofloxacin, Spironolactone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Spironolactone may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Spironolactone may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Mibefradil.]
[C07AA03, pindolol, Spironolactone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Spironolactone.]
[J01CA12, piperacillin, Spironolactone may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, Spironolactone may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[N06BX03, piracetam, Spironolactone may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Spironolactone.]
[N02AC03, pirinitramide, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Spironolactone.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Spironolactone.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Spironolactone.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Spironolactone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Spironolactone.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Spironolactone is combined with Polyethylene glycol.]
[C03AA05, polythiazide, Spironolactone may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, Spironolactone may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[A10BH03, saxagliptin, Spironolactone may increase the excretion rate of Saxagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA01, potassium chloride, The risk or severity of hyperkalemia can be increased when Potassium chloride is combined with Spironolactone.]
[V03AB21, potassium iodide, The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Spironolactone.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Spironolactone.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Spironolactone.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.]
[H02AB07, prednisone, Spironolactone may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Prenylamine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Spironolactone.]
[M04AB01, probenecid, Spironolactone may increase the excretion rate of Probenecid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA02, procainamide, Spironolactone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Spironolactone.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Spironolactone.]
[C10AB05, fenofibrate, Spironolactone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[R06AD02, promethazine, Spironolactone may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Propafenone.]
[A03AB05, propantheline, Spironolactone may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Spironolactone.]
[N02AC04, propoxyphene, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Spironolactone may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AB01, proscillaridin, Spironolactone may decrease the excretion rate of Proscillaridin which could result in a higher serum level.]
[N02CC04, rizatriptan, Spironolactone may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Spironolactone may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Spironolactone.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Spironolactone.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Spironolactone.]
[N07XX07, dalfampridine, Spironolactone may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Spironolactone may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Spironolactone may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Spironolactone.]
[C01BA01, quinidine, Quinidine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Spironolactone.]
[A02BA02, ranitidine, Spironolactone may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Rescinnamine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[J05AP01, ribavirin, Spironolactone may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Spironolactone.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Spironolactone.]
[N02BA05, salicylamide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Spironolactone.]
[A07EC01, sulfasalazine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Spironolactone.]
[S01BC08, salicylic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Spironolactone.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Spironolactone.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Spironolactone.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Spironolactone is combined with Obinutuzumab.]
[A12CD01, sodium fluoride, Spironolactone may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Spironolactone.]
